Huo, Yong http://orcid.org/0000-0002-5407-8773
Van de Werf, Frans
Han, Yaling
Rossello, Xavier
Pocock, Stuart J.
Chin, Chee Tang
Lee, Stephen W.-L.
Li, Yi
Jiang, Jie
Vega, Ana Maria
Medina, Jesús
Bueno, Héctor
Funding for this research was provided by:
AstraZeneca
Article History
Accepted: 16 October 2020
First Online: 4 February 2021
Declarations
:
: EPICOR and EPICOR Asia were funded by AstraZeneca. As they were noninterventional studies, no drugs were supplied or funded.
: F. Van de Werf has received consulting fees and research grants from Boehringer Ingelheim and Merck and consulting fees from Roche, Sanofi-Aventis, AstraZeneca, and The Medicines Company. S.J. Pocock has received research funding from AstraZeneca. C.T. Chin has received research support from Eli Lilly and honoraria from Medtronic and has been a consultant or advisory board member for AstraZeneca. A.M. Vega is a former employee of AstraZeneca. J. Medina is an employee of AstraZeneca. H. Bueno receives research funding from the Instituto de Salud Carlos III, Spain (PIE16/00021 and PI17/01799), Sociedad Española de Cardiología, AstraZeneca, Bayer, BMS, and Novartis; has received consulting fees from AstraZeneca, Bayer, BMS-Pfizer, and Novartis; and speaking fees or support for attending scientific meetings from Amgen, AstraZeneca, Bayer, BMS-Pfizer, Novartis, and MEDSCAPE-the heart.org. X. Rossello has received support from the SEC-CNIC CARDIOJOVEN fellowship program. Y. Huo, Y. Han, S. W.-L. Lee, Y. Li, and J. Jiang have no conflicts of interest that are directly relevant to the content of this article. AstraZeneca reviewed the manuscript during development and could make suggestions; however, final content, opinions, conclusions, and interpretation of the data are the responsibility of the authors. Professor Huo had full access to all of the data in the studies and takes responsibility for the integrity of the data and the accuracy of the data analysis.
: Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca’s data sharing policy described at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
: In both EPICOR and EPICOR Asia, the final study protocol was approved by the ethics committees of participating centers according to local regulations. The studies were performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
: All patients provided written informed consent at discharge from hospital and completed a contact order form agreeing to be contacted by telephone for regular follow-up interviews post discharge.
: Conceptualization: Yong Huo, Héctor Bueno, Stuart Pocock, and Ana Maria Vega (equal). Formal analysis: Stuart Pocock and Richard Cairns of Worldwide Clinical Trials (equal). Funding acquisition: Ana Maria Vega and Jesús Medina (equal). Investigation: Yong Huo, Frans Van de Werf, Yaling Han, Xavier Rossello, Chee Tang Chin, Stephen W-L Lee, Yi Li, Jie Jiang, and Héctor Bueno (equal). Methodology: Yong Huo, Héctor Bueno, Stuart Pocock, Ana Maria Vega, and Jesús Medina (equal). Project administration: Yong Huo and Héctor Bueno (equal). Resources: Ana Maria Vega and Jesús Medina (equal). Supervision: Yong Huo and Héctor Bueno (equal). Validation: Yong Huo, Héctor Bueno, and Stuart Pocock (equal). Visualization: Yong Huo, Héctor Bueno, and Stuart Pocock (equal). Writing – original draft: Yong Huo, Héctor Bueno, Stuart Pocock, and Xavier Rossello (equal). Writing – review and editing: All authors (equal).
: The authors thank Richard Cairns of Worldwide Clinical Trials (Nottingham, UK) for statistical analysis. Editorial support was provided by Carl V Felton PhD of Prime Global (Knutsford, Cheshire, UK), according to Good Publication Practice guidelines, and was funded by AstraZeneca.